Rising Prevalence Of Chronic Pain Conditions Propelling The Growth Of The Market Due To Increasing Demand For Chronic Pain Management And Expanding Ageing Population Is Supporting Development Across The Postherpetic Neuralgia (PHN) Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Expansion Is Expected For The Postherpetic Neuralgia (PHN) Market Over The Forecast Period?

The market for postherpetic neuralgia (phn) has seen robust growth in recent years. It is projected to increase from $0.77 billion in 2025 to $0.82 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. This historical expansion can be attributed to factors such as the increasing incidence of herpes zoster infections, limited available treatment options for neuropathic pain, a prevalent reliance on opioid-based pain management, the expanding elderly population, and the gradual growth of hospital pain management services.

The postherpetic neuralgia (phn) market size is anticipated to show significant expansion in the next few years, projected to reach $1.06 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. This growth during the forecast period is attributed to the development of targeted neuropathic pain therapies, the rising adoption of biologic and branded drugs, the expansion of online pharmacy distribution channels, an increasing focus on patient-centric pain management, and the growth of outpatient and ambulatory care facilities. Prominent trends expected in this period include the rising prevalence of shingles in the aging population, the increasing adoption of non-opioid pain management therapies, the growing use of transdermal and topical pain relief solutions, a higher demand for long-term chronic pain management, and improved awareness and early diagnosis of phn.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24664&type=smp

What Important Drivers Are Powering The Postherpetic Neuralgia (PHN) Market Growth?

The rising occurrence of chronic pain conditions is anticipated to drive the expansion of the postherpetic neuralgia (PHN) market in the future. Chronic pain is defined as enduring or repeated discomfort that persists for over 3 months, frequently extending past the typical duration of a sickness or wound, thereby impacting an individual’s daily activities and overall well-being. The widespread presence of chronic pain conditions stems from the aging demographic, given that seniors are more susceptible to degenerative ailments such as arthritis and neuropathy, which result in ongoing pain. Postherpetic neuralgia proves beneficial for chronic pain investigations because it offers a distinct framework for examining nerve-associated pain pathways and assessing prolonged therapeutic approaches. As an illustration, in January 2024, data from a report issued by the Office for Health Improvement and Disparities, a UK government body, indicated that approximately 18.4% of individuals aged 16 and over reported suffering from a long-term musculoskeletal (MSK) condition in 2023, representing an increase from 17.6% in 2022. Consequently, the growing occurrence of chronic pain conditions is fueling the expansion of the postherpetic neuralgia (PHN) market.

How Is The Postherpetic Neuralgia (PHN) Market Distributed Across Key Segments?

The postherpetic neuralgia (phn) market covered in this report is segmented –

1) By Type: Patches, Drugs, Opioids

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End Users: Hospitals, Clinics, Other End Users

Subsegments:

1) By Patches: Transdermal Drug Delivery Patches, Analgesic Patches

2) By Drugs: Prescription Drugs, Over-The-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologic Drugs

3) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic Opioids, Opioid Analgesics, Opioid Antagonists

Which Trends Are Shaping The Postherpetic Neuralgia (PHN) Market Landscape?

Leading companies in the postherpetic neuralgia (PHN) market are focusing on securing regulatory approvals to broaden their product offerings, gain a competitive edge, and address the considerable unmet clinical need for more effective and tolerable treatments. Regulatory approvals signify the official permissions granted by governmental health bodies, allowing a drug or therapy to be legally marketed and used for a specific medical condition. For example, in February 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical company, obtained final United States Food and Drug Administration approval to manufacture and market once-daily generic Gabapentin Tablets in 300 mg and 600 mg strengths, indicated for the management of postherpetic neuralgia (PHN). These gabapentin tablets are designed for treating PHN, which is a form of neuropathic pain resulting from nerve damage caused by the reactivation of the varicella-zoster virus. For PHN, the typical dosing begins with 300 mg on the first day, increases to 600 mg (300 mg twice daily) on the second day, and 900 mg (300 mg three times daily) on the third day, with titration up to a maximum of 1800 mg per day (600 mg three times daily) as necessary for pain relief.

Which Firms Are Competing In The Postherpetic Neuralgia (PHN) Market?

Major companies operating in the postherpetic neuralgia (phn) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Haisco Pharmaceutical Group Co. Ltd., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Sanofi S.A., Grünenthal GmbH, Endo International plc, Purdue Pharma L.P., Hikma Pharmaceuticals plc, Cipla Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd.

Access The Complete Postherpetic Neuralgia (PHN) Market Report:

https://www.thebusinessresearchcompany.com/report/postherpetic-neuralgia-phn-global-market-report

Which Region Is The Dominant Market In The Postherpetic Neuralgia (PHN) Market?

North America was the largest region in the postherpetic neuralgia (PHN) market in 2025. The regions covered in the postherpetic neuralgia (phn) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Postherpetic Neuralgia (PHN) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24664&type=smp

Browse Through More Reports Similar to the Global Postherpetic Neuralgia (PHN) Market 2026, By The Business Research Company

Neuralgia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Breast Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-implants-global-market-report

Ocular Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/ocular-implants-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795